GS
FLNA

GTS Securities’s Filana Therapeutics FLNA Stock Holding History

GTS Securities’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-117,800
Closed -$3.47M – 3523
2024
Q3 		$3.47M Buy
117,800
+85,700
+267% +$1.97M 0.01% 1160
2024
Q2 		$396K Sell
32,100
-11,500
-26% -$242K ﹤0.01% 2896
2024
Q1 		$885K Sell
43,600
-16,000
-27% -$369K ﹤0.01% 2071
2023
Q4 		$1.34M Buy
59,600
+4,000
+7% +$84.5K ﹤0.01% 1953
2023
Q3 		$925K Buy
+55,600
New +$1.1M ﹤0.01% 2078

Other funds holding FLNA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
National Bank of Canada
National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return

GTS Securities's FLNA Position: Q3 2023 in Review

GTS Securities sold out of Filana Therapeutics (FLNA) in Q3 2023, closing a stake of 30,336 shares — an estimated $601K sold.

GTS Securities first reported a position in FLNA in Q2 2023 and held it in 1 quarter. The position peaked at $744K in Q2 2023. 140 funds tracked by Wall St. Rank hold FLNA as of Q3 2023.

  • GTS Securities reported no remaining Filana Therapeutics position as of Q3 2023 after selling out during the quarter.
  • GTS Securities sold 30,336 Filana Therapeutics shares in Q3 2023, an estimated $601K.
  • GTS Securities first reported a position in Filana Therapeutics in Q2 2023 and held it in 1 quarter.
  • GTS Securities's Filana Therapeutics position peaked at $744K in Q2 2023.
  • 140 funds tracked by Wall St. Rank held Filana Therapeutics as of Q3 2023.

Based on GTS Securities's 13F filing for Q3 2023, filed 15 Nov 2023.